Search Results - david+eisenberg

3 Results

Sort By:

Compounds that Disaggregate Alzheimer's Disease-Associated Fibrils of Tau Protein (UCLA Case No. 2022-145, 2025-329)

Contact UCLA Technology Development Group to learn more.

Published: 9/19/2025 | Inventor(s): David Eisenberg

Keywords(s):

Category(s): Therapeutics > CNS and Neurology

2019-701 PEPTIDE-BASED INHIBITORS THAT BLOCK AGGREGATION, SEEDING AND CROSS-SEEDING OF AMYLOID BETA AND TAU

UCLA researchers in the Department of Chemistry and Biochemistry have developed novel therapeutics for Alzhiemer’s Disease and other tauoapathies. BACKGROUND:Alzhiemer’s Disease (AD) is a severe neurodegenerative disease characterized by deterioration of the brain cells and loss of multiple cognitive functions. Although AD is the most...

Published: 7/17/2025 | Inventor(s): David Eisenberg, Paul Seidler

Keywords(s): Cns, Therapeutics & Vaccines

Category(s): Therapeutics > CNS and Neurology

2016-694 INHIBITION OF THE AGGREGATION OF TRANSTHYRETIN BY SPECIFIC BINDING OF PEPTIDES TO AGGREGATION-DRIVING SEGMENTS

Inhibition of the Aggregation of Transthyretin by Specific Binding of Peptides to Aggregation-Driving SegmentsSUMMARYUCLA researchers from the Department of Chemistry and Biochemistry have developed a novel process to inhibit amyloid aggregation of Transthyretin, which is associated with three debilitating disorders including senile systemic amyloidosis...

Published: 7/17/2025 | Inventor(s): David Eisenberg, Lorena Saelices Gomez

Keywords(s): Cardiovascular, Cns, Genetic Disease, Hematology, Therapeutics & Vaccines

Category(s): Therapeutics, Therapeutics > Cardiovascular, Therapeutics > Hematology, Therapeutics > CNS and Neurology